Skip to main content
ZYME
NASDAQ Life Sciences

Zymeworks Reports Strong FY25 Results, Secures $250M Non-Dilutive Financing, and Advances Lead Asset Towards US Launch

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$23.4
Mkt Cap
$1.756B
52W Low
$9.03
52W High
$28.49
52W Position info
159% above low
Off High info
18% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ZYME has more than doubled off its 52-week low of $9.03.

Summary

Zymeworks reported strong financial results for 2025, secured $250.0 million in non-dilutive financing, and made significant progress with its lead asset, Ziihera, including an upcoming sBLA submission and substantial milestone potential, extending its cash runway beyond 2028.


Key Events · Financing and Capital Events · ZYME

  • Strong Financial Performance

    Reported total revenue of $106.0 million for 2025, a 39% increase compared to 2024, and reduced net loss by 34% to $81.1 million for the year.

  • $250M Non-Dilutive Royalty-Backed Financing

    Entered into a $250.0 million non-recourse royalty-backed note financing arrangement with Royalty Pharma, providing non-dilutive capital to support strategic initiatives.

  • Significant Share Repurchase Activity

    Utilized approximately $62.5 million of its $125.0 million authorized share repurchase program, acquiring 2,580,415 shares at an average price of $24.22.

  • Key Regulatory Progress for Ziihera

    Partner Jazz Pharmaceuticals expects to complete the supplemental Biologics License Application (sBLA) submission for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma (GEA) in 1Q 2026, with a potential U.S. launch in 2H 2026.


Analysis · ZYME · Life Sciences

This filing presents a highly positive and comprehensive update for Zymeworks, combining strong financial performance with significant strategic capital and product development milestones. The $250.0 million non-dilutive royalty-backed financing provides substantial capital without shareholder dilution, while the ongoing $62.5 million share repurchase demonstrates a commitment to returning value. Critically, the imminent sBLA submission for Ziihera in a major indication (HER2+ GEA) and the potential for $440.0 million in associated milestones, coupled with an extended cash runway beyond 2028, significantly de-risk the company's future and provide clear catalysts for growth. Investors should view this as a strong signal of operational execution and strategic financial management.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZYME was trading at $23.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.03 to $28.49. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZYME - Latest Insights

ZYME
Nov 16, 2026, 6:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $26.30
Real-time Price: $27.00 info
Change: +$0.700 (+3%) info
Market Cap: $1.826B info
ZYME
Nov 09, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $27.00 info
Change: -$3.81 (-12%) info
Market Cap: $1.826B info
ZYME
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $27.00 info
Change: -$3.81 (-12%) info
Market Cap: $1.826B info
ZYME
Nov 09, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.81
Real-time Price: $27.00 info
Change: -$3.81 (-12%) info
Market Cap: $1.826B info
ZYME
Oct 24, 2026, 2:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.55
Real-time Price: $27.00 info
Change: -$1.55 (-5%) info
Market Cap: $1.826B info